Business Wire

KINAXIS

11.1.2024 13:01:50 CET | Business Wire | Press release

Share
Kinaxis Rolls Out New Innovations to Revolutionize Stretched Retail Supply Chains

Kinaxis® Inc. (TSX: KXS), the leading supply chain management platform, today announced an expansion of its retail offering with the release of multiple new AI- and ML-powered innovations that provide retailers with end-to-end supply chain transparency, demand forecasting, and powerful simulation scenario planning capabilities to ensure customers can buy the goods they want, when and where they want them, regardless of unforeseen disruptions.

From unpredictable demand spikes driven by changing consumer habits and the rise of omni-channel commerce that seeks to provide a seamless shopping experience across multiple touchpoints, the retail landscape has never been more competitive, with retailers’ supply chains facing countless challenges that threaten their ability to keep customers happy and turn a profit.

Designed to simplify retailers’ ability to successfully manage the complexity of countless locations, SKUs, promotions and inventory variables that demand unparalleled decision-making, Kinaxis’ enhanced retail offering now includes:

  • Demand.AI innovations – powerful machine-learning based models tailored to the scale and complexity of retailers that enables better understanding of how both internal (e.g. frequent price changes, new product introductions, changes to promotional plans) and external factors (e.g. social sentiment, weather, shifts in consumer behavior, local/national events) are influencing short and long-term demand for their products, and which can inform actions to maximize revenue opportunities and proactively resolve risks.
  • Replenishment Planning – an all-new capability that enables retailers to better manage replenishment parameters across their supply chain to ensure every item at every store and distribution center gets restocked in a timely manner while establishing guardrails to protect stores from shipping excess inventory that would exceed their shelf-life capacity and increase their inventory holding costs.
  • Demand Planning innovations – provides retailers with easy-to-interpret visualizations that explain demand patterns while enabling them to make instant adjustments to forecasts based on human insights around trends at any part of their supply chains, by product, geography, store, SKU, day and more.

“Faced with ever increasing consumer expectations, today’s retailers are in desperate need of solutions that enable them to make confident decisions around their supply chains at scale,” said Andrew Bell, chief product officer at Kinaxis. “With these latest innovations, businesses will finally be able to take the guesswork out of demand and replenishment planning with a view to creating a seamless and resilient end-to-end supply chain. And with additional investments on the horizon in promotion planning and allocation, we’re confident that retailers will continue to look to Kinaxis to help them provide their customers with the best products while ensuring their shelves are always fully stocked.”

The new retail-focused product innovations will enable Kinaxis to strengthen its position within the sector including with new customers like sporting goods leader Brooks Running and existing partners like HAVI, one of the world’s foremost experts in supply chain integration. Last year, Kinaxis and HAVI announced they were joining forces to innovate and transform the Quick Service Restaurant industry.

“With the pace of doing business speeding up and consumer behavior changing by the minute, companies can no longer rely on incremental improvements to their supply chain, which is why we were so thrilled to partner with Kinaxis who have proven their mettle for meeting the demanding needs of customers regardless of the industry,” said Rodney Brown, senior vice president and chief supply chain officer, North America and global planning and analytics at HAVI. “We’re eager to roll out these state-of-the-art capabilities to some of our largest customers and anticipate that they will immediately see the value they bring to their overall business.”

With more than 40,000 users in 100+ countries, Kinaxis works with some of the world’s biggest brands across all sectors including CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end to end from strategic planning to last-mile delivery.

Kinaxis’ retail product innovations will be showcased at NRF 2024 from January 14 – 16, 2024, at the Jacob K. Javits Convention Center in New York City. Visit Kinaxis at Booth #4068.

About Kinaxis

Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240111554461/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye